All Relations between Schizophrenia and Aripiprazole

Publication Sentence Publish Date Extraction Date Species
Marilyn A Davies, Douglas J Sheffler, Bryan L Rot. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS drug reviews. vol 10. issue 4. 2005-02-17. PMID:15592581. at recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder. 2005-02-17 2023-08-12 Not clear
Nandini Chakraborty, Timothy Johnsto. Aripiprazole and neuroleptic malignant syndrome. International clinical psychopharmacology. vol 19. issue 6. 2005-02-15. PMID:15486522. we report our first patient to receive this drug, who had treatment-resistant schizophrenia and developed neuroleptic malignant syndrome (nms) with aripiprazole. 2005-02-15 2023-08-12 Not clear
Subramoniam Madhusoodanan, Ronald Brenner, Sanjay Gupta, Harsha Reddy, Olivera Bogunovi. Clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. CNS spectrums. vol 9. issue 11. 2005-02-08. PMID:15520608. clinical experience with aripiprazole treatment in ten elderly patients with schizophrenia or schizoaffective disorder: retrospective case studies. 2005-02-08 2023-08-12 Not clear
Robert D McQuade, Elyse Stock, Ron Marcus, Darlene Jody, Neveen A Gharbia, Simon Vanveggel, Don Archibald, William H Carso. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. The Journal of clinical psychiatry. vol 65 Suppl 18. 2005-02-01. PMID:15600384. the primary objective of this double-blind study was to compare the safety and tolerability of aripiprazole and olanzapine in patients with schizophrenia as evidenced by the percentage of patients exhibiting significant weight gain. 2005-02-01 2023-08-12 Not clear
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. aripiprazole, a quinolinone derivative, is an atypical antipsychotic drug indicated for the treatment of adult patients with schizophrenia. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. aripiprazole 10 or 15 mg once daily is effective and well tolerated in patients with schizophrenia or schizoaffective disorder. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. aripiprazole is a valuable new therapeutic option in the management of patients with schizophrenia. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. the mechanism of action of aripiprazole is not yet known, but evidence suggests that its efficacy in the treatment of the positive and negative symptoms of schizophrenia and its lower propensity for extrapyramidal symptoms (eps) may be attributable to aripiprazole's partial agonist activity at dopamine d2 receptors. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. therapeutic efficacy: the efficacy of aripiprazole has been demonstrated in patients with schizophrenia or schizoaffective disorder. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. in general, significant reductions from baseline in mean positive and negative syndrome scale total, positive and negative symptom scores, and clinical global impression severity of illness scores were observed in patients with acute relapse of chronic schizophrenia or schizoaffective disorder receiving recommended (10 or 15 mg/day) or higher-than-recommended (20 or 30 mg/day) dosages of aripiprazole versus those receiving placebo in three well controlled, short-term trials. 2004-11-15 2023-08-12 human
Tracy Swainston Harrison, Caroline M Perr. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. vol 64. issue 15. 2004-11-15. PMID:15257633. in a nonblind, 26-week trial, patients with chronic schizophrenia receiving aripiprazole 30 mg/day experienced similar (general cognitive function) or better (verbal learning) changes from baseline in the neurocognitive parameters evaluated compared with recipients of olanzapine 10-15 mg/day. 2004-11-15 2023-08-12 human
H G El-Sayeh, C Morgant. Aripiprazole for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2004-08-17. PMID:15106256. aripiprazole for schizophrenia. 2004-08-17 2023-08-12 Not clear
Ann M Mortime. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence-based mental health. vol 7. issue 2. 2004-05-19. PMID:15107337. aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. 2004-05-19 2023-08-12 Not clear
Jeffrey A Lieberma. Dopamine partial agonists: a new class of antipsychotic. CNS drugs. vol 18. issue 4. 2004-05-10. PMID:15015905. aripiprazole produced significant improvements in positive and negative symptoms in short- and long-term studies of patients with schizophrenia or schizoaffective disorder. 2004-05-10 2023-08-12 Not clear
Jeffrey A Lieberma. Dopamine partial agonists: a new class of antipsychotic. CNS drugs. vol 18. issue 4. 2004-05-10. PMID:15015905. in conclusion, the findings from clinical studies of aripiprazole show that dopamine partial agonists offer a novel, effective and well-tolerated treatment approach for patients with schizophrenia. 2004-05-10 2023-08-12 Not clear
Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. 2004-05-06 2023-08-12 Not clear
Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. 2004-05-06 2023-08-12 Not clear
Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. the long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. 2004-05-06 2023-08-12 Not clear
Siegfried Kasper, Mark N Lerman, Robert D McQuade, Anutosh Saha, William H Carson, Mirza Ali, Donald Archibald, Gary Ingenito, Ronald Marcus, Teresa Pigot. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. The international journal of neuropsychopharmacology. vol 6. issue 4. 2004-05-06. PMID:14609439. aripiprazole represents a promising new option for the long-term treatment of schizophrenia. 2004-05-06 2023-08-12 Not clear